Comparative Pharmacology
Head-to-head clinical analysis: MANNITOL 20 versus OSMITROL 15 IN WATER IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MANNITOL 20 versus OSMITROL 15 IN WATER IN PLASTIC CONTAINER.
MANNITOL 20% vs OSMITROL 15% IN WATER IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases plasma osmolality, drawing water from intracellular and interstitial spaces into the extracellular fluid, thereby reducing intracranial pressure and promoting diuresis.
Osmotically active agent that increases plasma osmolality, drawing water from intracellular and interstitial spaces into the vascular compartment, thereby reducing cerebral edema and intraocular pressure.
Adult: 50-100 g intravenously as a 20% solution over 30-60 minutes. For cerebral edema: 0.25-1 g/kg IV over 30-60 minutes. For oliguric acute kidney injury: test dose 0.2 g/kg IV over 3-5 minutes.
1.5-2 g/kg intravenous infusion over 30-60 minutes every 6-8 hours as needed for reduction of intracranial pressure or cerebral edema.
None Documented
None Documented
Terminal elimination half-life 1.1–1.6 hours in normal renal function; prolonged to 18–36 hours in anuria/end-stage renal disease.
Terminal half-life: 0.25–1.5 hours (15–90 minutes) in normal renal function; prolonged to 24–36 hours in anuria or severe renal impairment.
Renal, >90% unchanged by glomerular filtration; negligible biliary (<2%) or fecal elimination.
Renal: >90% unchanged by glomerular filtration; minimal tubular reabsorption or secretion. <10% metabolized in liver (negligible).
Category A/B
Category C
Osmotic Diuretic
Osmotic Diuretic